Search

Introduction: Increased cardiovascular (CV) morbidity and mortality is observed in inflammatory joint diseases (IJDs) such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. However, the management of CV disease in these conditions is far from being well established. Areas covered: This review summarizes the main epidemiologic, pathophysiological, and clinical risk factors of CV disease associated with IJDs. Less common aspects on early diagnosis and risk stratification of the CV disease in these conditions are also discussed. In Europe, the most commonly used risk algorithm in patients with IJDs is the modified SCORE index based on the revised recommendations proposed by the EULAR task force in 2017. Expert opinion: Early identification of IJD patients at high risk of CV disease is essential. It should include the use of complementary noninvasive imaging techniques. A multidisciplinary approach aimed to improve heart-healthy habits, including strict control of classic CV risk factors is crucial. Adequate management of the underlying IJD is also of main importance since the reduction of disease activity decreases the risk of CV events. Non-steroidal anti-inflammatory drugs may have a lesser harmful effect in IJD than in the general population, due to their anti-inflammatory effects along with other potential beneficial effects. [ABSTRACT FROM AUTHOR]

Correction to: Rheumatology and Therapy (2022) 9:589-608 https://doi.org/10.1007/s40744-021-0... In the original publication of the article, the authors noticed some of the values in Table 1 and Table 2 of this article, the data in the column 2 and row 67 headed "Baseline patient sociodemographic and clinical characteristics" and the data in the column 3 and row 12 headed "Number of RA treatments received prior to baricitinib treatment" were incorrectly published. The original article can be found online at https://doi.org/10.1007/s40744-021-00423-8. [Extracted from the article]